Evaluation of Tafasitamab plus Rituximab and Lenalidomide in patients with Lymphoma that has stopped responding to treatment

Purpose

The purpose of this trial is to study whether the condition of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma improves on tafasitamab as an add-on to rituximab and lenalidomide.

Costs

Participation in the clinical trial is free of charge.

Condition

Lymphoma

Trial phase

Phase 3 trial (what are the 4 phases of clinical trials?)

Countries

Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom

Which Lymphoma patients can access this clinical trial?

Patients who wish to participate in this clinical trial need to fulfill a number of eligibility criteria. Some are very specific and we will require the medical records from your doctor.

You could be eligible if:

  • You can take part in the trial in Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom;
  • You have a diagnosis of Grade 1, 2, or 3a Follicular Lymphoma (FL) or Marginal Zone Lymphoma, including extranodal, nodal, and splenic subtypes;
  • You have been treated with at least 1 anti-CD20 therapy (either alone or together with chemoimmunotherapy) and at least 6 doses of an anti-CD20 therapy;
  • Your disease has come back (relapsed) or became worse (progressed), or did not respond anymore to the most recent previous treatment;
  • You have at least one nodal tumor > 1.5 cm in longest diameter or at least one extranodal tumor > 1.0 cm in longest diameter;
  • You have a ECOG performance status score (scale to assess a patient’s daily living abilities) of fully active-0, slightly restricted-1, or slightly restricted-2.

If you meet all of these conditions you might be allowed to enter the screening process.

You are not eligible if:

  • You have congestive heart failure;
  • You have an HIV infection;
  • You have an active Hepatitis B or C infection that requires treatment or are at risk for HBV reactivation;
  • Your immune system is severely compromised;
  • You have a fast-growing central nervous system (CNS) lymphoma
  • You have a history of heart, CNS and/or other disease that might compromise your ability to participate in the study or to give informed consent;
  • You have been under treatment with rituximab plus lenalidomide.

If you meet all of these conditions you might be allowed to enter the screening process.

Learn how to access this clinical trial

If you meet the conditions and you would like to participate in this study, please register your interest by filling in the Participation Form and we will contact you shortly with additional information on the screening process.

Be fully informed before you show interest in taking part in this study

Joining a clinical trial study can be unnerving for both you and your loved ones, which is why you first need to consult your treating doctor to weigh up the pros and cons. We will try to give you all the information you and your doctor need, so you and your doctor can make the best decision for you.

Please be aware that as part of the screening process you and your doctor will need to send us your medical records.

Be aware:

  • Being selected for the study depends on whether you are eligible for the trial;
  • At all times your data will be kept safe and protected;
  • If you join the trial, you could be randomly assigned to a placebo group.

Yes, I want to participate

Fill in the form below so we can contact you with more details about this study.

Something is missing. You'll find more details highlighted below.

Thank you for registering your interest in this clinical trial!

We will get in touch with you shortly at . If you have any questions, send an email to [email protected]

462 Evaluation of Tafasitamab plus Rituximab and Lenalidomide in patients with Lymphoma that has stopped responding to treatment
US